drugset / Trial / NCT01510613

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

NCT01510613

Phase 2 Completed 28 enrolled Fondazione IRCCS Policlinico San Matteo di Pavia
NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to evaluate the safety and efficacy of Pomalidomide and Dexamethasone in patients who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or Cyclophosphamide) and Bortezomib. Patients who received 1 previous treatment without achieving a complete response (CR), but who could not be treated with alkylators and/or Bortezomib due to contraindications, will be included.

Timeline

Start
2012-02
Primary completion
2016-12
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 20 mg Oral
Subject Dexamethasone Small molecule 40 mg Oral
Subject Pomalidomide Other / unclassified 2 mg Oral
Subject Pomalidomide Other / unclassified 4 mg Oral

Indications